Lactucin alleviates liver fibrosis by regulating the TLR4-MyD88-MAPK/NF-κB signaling pathway through intestinal flora
Abstract
Ethnopharmacological relevance Cichorium glandulosum (CG) is a kind of traditional Chinese medicine, mainly produced in Xinjiang and Inner Mongolia, and its medicinal part is mainly the dried root of CG. CG is a commonly used medicine in Uygur medicine, which has good pharmacological effects. Lactucin (LC) in this study is the main sesquiterpene monomer compound obtained from the ethyl acetate extract of CG. The purity of LC obtained by our research group in the previous stage reached 98.1 %, which met the purity requirements of chemical control of traditional Chinese medicine. At present, the research on the pharmacological action of CG mainly focuses on the extract of CG, and there is little research on the monomer compounds and exact pharmacological action mechanism in CG. Aim of the study The aim of this study is to investigate the mechanism of lactucin (LC) in alleviating liver fibrosis by regulating TLR4-related inflammatory pathway through intestinal flora-intestine-liver axis. Materials and methods Firstly, the content of LC was determined by HPLC. In vitro, hepatic fibrosis cell model was induced and cytotoxicity was detected by MTT assay. QRT-PCR and Western Blot were used to detect the effect of LC on the expression of proteins related to TLR4-MyD88-MAPK/NF-κB signaling pathway. In vivo, carbon tetrachloride and dextran sodium sulfate were used to induce liver fibrosis and enteritis in rats. Detection of liver fibrosis index, H&E staining, Sirius red staining, immunofluorescence and Western Blot were used to detect the degree and action pathway of liver fibrosis. 16S rRNA analysis and bile acid targeted metabolism were used to explore the role of intestinal flora in liver fibrosis. Results In vitro, LC can significantly inhibit the mRNA levels of TLR4 and related inflammatory factors, inhibit the expression of TLR4-MyD88-MAPK/NF-κB pathway protein, and reduce the level of intracellular reactive oxygen species, with the same effect as TLR4 inhibitors. In vivo, experimental results show that LC can reduce the degree of liver fibrosis and colitis, significantly reduce the levels of MDA and MPO in colon tissue, increase the level of SOD, reduce the activities of HYP, AKP, AST, ALT, TBA and γ-GT in serum, and increase the level of Alb. LC can also inhibit the expression of TLR4-MyD88-MAPK/NF-κB pathway, and inhibit the expression of TLR4 protein in liver and increase the expression of ZO-1 protein in colon. In addition, LC can regulate the flora composition of liver fibrosis and improve bile acid metabolism. Conclusion This study found that LC can alleviate liver fibrosis, and suggested that the beneficial effect of LC on liver fibrosis may be achieved by regulating TLR4-MyD88-MAPK pathway and improving intestinal flora through intestinal liver axis. At the same time, it is revealed that LC is the main component of CG for treating liver fibrosis, which lays a theoretical foundation for the research and development of new drugs and clinical research of CG in the later period.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In human macrophages, reduced SUMOylation activates KLF4, which induces SOCS1 and inhibits JAK-STAT and TLR4-MyD88 signaling, thereby reducing NF-κB and MAP kinase activity and promoting restorative polarization.
“In human macrophages, reduced SUMOylation activates KLF4, which induces suppressor of cytokine signaling 1 (SOCS1) and inhibits JAK–STAT and TLR4–MyD88 signaling, thereby reducing NF-κB and MAP kinase activity and promoting restorative polarization (81–85).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [81]
Cites
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803 · see citing works
Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis
Wang, J., Zhu, N., Su, L., Gao, Y., & Yang, R. (2023) · Cells · doi:10.3390/cells12050793 · Cited by 624 · see citing works
Self-citationRole of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut
Seki, E., & Schnabl, B. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.219691 · Cited by 440 · see citing works
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430 · see citing works
Intestinal flora and disease mutually shape the regional immune system in the intestinal tract
Zhou, B., Yuan, Y., Zhang, S., Guo, C., Li, X., Li, G., Xiong, W., & Zeng, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00575 · Cited by 396 · see citing works
Schwimmer, J. B., Johnson, J. S., Angeles, J. E., Behling, C., Belt, P. H., Borecki, I., Bross, C., Durelle, J., Goyal, N. P., Hamilton, G., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.06.028 · Cited by 298 · see citing works
Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis
Khomich, O. A., Ivanov, A. V., & Bartosch, B. (2019) · Cells · doi:10.3390/cells9010024 · Cited by 227 · see citing works
Ohtani, N., & Kawada, N. (2019) · Hepatology Communications · doi:10.1002/hep4.1331 · Cited by 173 · see citing works
Raftar, S. K. A., Ashrafian, F., Yadegar, A., Lari, A., Moradi, H. R., Shahryari, A., Azimirad, M., Alavifard, H., Mohsenifar, Z., Davari, M., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00484-21 · Cited by 166 · see citing works
Hepatocyte nuclear factor 4α attenuates hepatic fibrosis in rats
Yue, H.-Y., Yin, C., Jl, H., Zeng, X. Y., Chen, Y., Zhong, W. H., Hu, P.-F., Deng, X., Tan, Y.-X., Zhang, J.-P., et al. (2009) · Gut · doi:10.1136/gut.2008.174904 · Cited by 159 · see citing works
Masse, K. E., & Lu, V. B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1169624 · Cited by 120 · see citing works
Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: An input for novel therapies
Frăsinariu, O. E., Ceccarelli, S., Alisi, A., Moraru, E., & Nobili, V. (2012) · Digestive and Liver Disease · doi:10.1016/j.dld.2012.11.010 · Cited by 97 · see citing works
Rajapakse, J., Khatiwada, S., Akon, A. C., Yu, K. L., Shen, S., & Zekry, A. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2240031 · Cited by 94 · see citing works
Shi, H. M., Zhou, P., Gao, G., Liu, P., Wang, S., Song, R., Zou, Y., Yin, G., & Wang, L. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.13757 · Cited by 93 · see citing works
Nie, Y., Liu, Q., Zhang, W., Wan, Y., Huang, C., & Zhu, X. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1972746 · Cited by 88 · see citing works
Cheng, C., Tan, J., Qian, W., Zhang, L., & Hou, X. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.08.017 · Cited by 86 · see citing works
The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis
Zhang, Y., Li, Z.-J., Gou, H.-Z., Song, X., & Zhang, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.945368 · Cited by 74 · see citing works
Wang, C., Ma, C., Fu, K., Gong, L., Zhang, Y., Zhou, H., & Li, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.756924 · Cited by 69 · see citing works
Meng, X., Kuang, H., Wang, Q., Zhang, H., Wang, D., & Kang, T.-G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110180 · Cited by 69 · see citing works
Bai, X., Fu, R., Duan, Z., Liu, Y., Zhu, C., & Fan, D. (2021) · Food & Function · doi:10.1039/d1fo00242b · Cited by 56 · see citing works
Pan, Q., Gao, M., Kim, D.-M., Ai, W., Yang, W., Jiang, W. G., Brashear, W. A., Dai, Y., Li, S., Sun, Y., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.08.013 · Cited by 51 · see citing works
Synergistic anti-inflammatory effect of gut microbiota and lithocholic acid on liver fibrosis
Shao, J., Ge, T., Tang, C., Wang, G., Pang, L., & Chen, Z. (2022) · Inflammation Research · doi:10.1007/s00011-022-01629-4 · Cited by 46 · see citing works
Han, C. L., Wu, X., Zou, N., Zhang, Y., Yuan, J., Gao, Y., Chen, W., Yao, J., Li, C., Hou, J., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683613 · Cited by 44 · see citing works
Self-citationGut Microbiome Contributes to Liver Fibrosis Impact on T Cell Receptor Immune Repertoire
Liang, Q. D., Zhang, M., Hu, Y., Zhang, W., Zhu, P., Chen, Y., Xue, P., Li, Q., & Wang, K. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.571847 · Cited by 32 · see citing works
Ogaly, H. A., Eltablawy, N. A., & Abd‐Elsalam, R. M. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/4039753 · Cited by 31 · see citing works
Zhao, Y., Zhao, M., Zhang, Y., Fu, Z., Jin, T., Song, J., Huang, Y., Zhao, C., & Wang, M. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117383 · Cited by 30 · see citing works
Li, Z., Dong, J., Wang, M., Yan, J., Hu, Y., Liu, Y., Pan, Y., & Li, H. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00463-y · Cited by 29 · see citing works
Dang, T., Zheng, G., Zhang, Q., Jin, P., Zhang, H., Su, L., Qin, D., & Yao, G. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.104170 · Cited by 28 · see citing works
Self-citationLiao, X., Zhan, W., Tian, T., Yu, L., Li, R., & Yang, Q. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29520 · Cited by 22 · see citing works
Huo, J., Pei, W., Liu, G., Sun, W., Wu, J., Huang, M., Lü, W., Sun, J., & Sun, B. (2023) · Foods · doi:10.3390/foods12030450 · Cited by 19 · see citing works
Liu, Y., Niu, G., Li, C., Guo, J., Song, J. M., Li, H., & Zhang, X. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.695019 · Cited by 17 · see citing works
Abdo, A. A. A., Zhang, C., Al‐Dalali, S., Hou, Y., Gao, J., Yahya, M. A., Saleh, A. Y., Aleryani, H., Al-Zamani, Z. A. S., & Sang, Y. (2023) · Nutrients · doi:10.3390/nu15132923 · Cited by 14 · see citing works
Dong, K., Yang, L., Gao, Z., Wu, X., Liu, C., Zhang, J., & Zhang, H. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467216666230322113039 · Cited by 12 · see citing works
Qin, D., Han, C. L., Gao, Y., Li, H., & Zhu, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-70253-5 · Cited by 12 · see citing works
Self-citationShen, B., Zhou, C., Gu, T., Shen, Z., Guo, Y., Dai, W., Liu, Y., Zhang, J., Lu, L., & Dong, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1080226 · Cited by 10 · see citing works
Yao, Y., Zhang, L., Cheng, F., Jiang, Q., Ye, Y., Ren, Y., He, Y., Su, D., Cheng, L., Shi, G., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03416-2 · Cited by 8 · see citing works
Flagged first, then by citations
1 of the 37 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Liu, S., Liao, Z., Liu, Y., Bai, J., Huang, Z., Cao, X., Shen, C., Niu, S., & Guo, J. (2025) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.70265 · Cited by 3 · see citing works
Ma, X., Aibaidula, Y., Zhang, C., Qi, S., Pang, T., Zhang, J., Hou, W., & Ma, X. (2025) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2025.08.001 · Cited by 3 · see citing works
Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
Aquino, J. B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1792423 · Cited by 1 · see citing works
Zhang, X., Luo, Q., Hu, Y., Gong, P., Zhang, Y., & Zhang, L. (2025) · Biomolecules · doi:10.3390/biom15101449 · Cited by 1 · see citing works
Ma, X., Qi, S., Qi, S., Zhang, J., Zhang, J., Pang, T., Hou, W., & Ma, X. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-02076-3 · Cited by 1 · see citing works
Tan, W., Li, X., & Tang, X. (2025) · Journal of Medical Biochemistry · doi:10.5937/jomb0-58247 · Cited by 1 · see citing works
Lactobacillus combination alleviates dextran sulfate sodium-induced colitis in Wuzhishan minipigs
Wang, X., Ma, X., Zhang, X., He, Y., Chen, Y., Fu, Q., Yang, Y., Yin, X., & Wu, Z. (2026) · Food & Function · doi:10.1039/d4fo04728a · Cited by 1 · see citing works
Li, J., Zhao, Y., Ma, Y., Xie, B., Huang, L., Yang, H., Ma, X., Deng, H., Wang, S., Sun, C., et al. (2026) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2500607 · Cited by 1 · see citing works
Xiao, Z., Guo, M., Tang, W., Chen, M., & Yang, Q. (2025) · Research Square · doi:10.21203/rs.3.rs-6224838/v1 · Cited by 1 · see citing works
Meng, Z., Zhang, Q., Zhao, Z., Zhang, Y., Lu, Z., Liu, G., Xiang, W., Zhang, Q., & Tang, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1812651
Chen, S., Chen, H., Xie, J., Peng, X., Yang, S., Yin, D., & Zhu, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1752309
- Authors
- Zhu, L., Lv, B., Gao, Y., & Qin, D.
- Affiliations
- Shihezi University (CN)
- Henan University of Science and Technology (CN)
- Corresponding author
- Qin, Dongmei
- Venue
- Archives of Biochemistry and Biophysics
- Publisher
- Elsevier BV
- Published
- 2025-04
- Volume
- 766
- Pages
- 110341
- ISSN
- 0003-9861 (ISSN-L)
- OpenAlex
- W4407392850
- Cited by
- 11
- References
- 37
- Citations by year
- 2026: 5 · 2025: 6
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Archives of Biochemistry and Biophysics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Xinjiang Production and Construction Corps
- National Natural Science Foundation of China
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Keywords
- lactucin, liver fibrosis, gut microbiota, gut-liver axis, intestinal inflammation, sesquiterpenes, bile acid metabolism, reactive oxygen species, colitis, carbon tetrachloride-induced fibrosis
- MeSH terms
- Gastrointestinal Microbiome, Animals, Humans, Liver Cirrhosis, Male, Sesquiterpenes, Signal Transduction, NF-kappa B, Rats, Sprague-Dawley, MAP Kinase Signaling System, Toll-Like Receptor 4, Rats, Myeloid Differentiation Factor 88
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review